The Greater Cannabis Company, Inc. (GCAN)
OTC Markets OTCQB
Fundamentals
Valuation and ratings
The Greater Cannabis Company, Inc. trades at USD0.27. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About The Greater Cannabis Company, Inc.
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.
The full research page for GCAN, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.